Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer to Enhance Its Presence in Dermatology
June 14, 2010
- New Taiyo Yakuhin May Consider IPO: President Aratani
June 14, 2010
- Miraka HD: Sales Up 2.6% to ¥149,074 Mil.
June 14, 2010
- CMIC: Half-Year Sales Up 12.7% to ¥16 Bil.
June 14, 2010
- Nihon Chouzai to Open 30 Pharmacies Downtown
June 14, 2010
- Takara's Technology Supports Bio Research in Japan: President Ohmiya
June 14, 2010
- MSNW: Dispensing Pharmacy Business Boosts Sales, Profits
June 14, 2010
- Kyowa Kirin Licenses KW-6002 to BLS in North America
June 14, 2010
- JDS HbA1c Values to Be Replaced with NGSP HbA1c Values
June 14, 2010
- Astellas to Copromote Kaketsuken's Vaccines in Kyushu
June 14, 2010
- Novartis to Drive Business by Expanding Range of Indications for Afinitor: Mr Asakawa
June 14, 2010
- Naoto Kan Elected 94th Prime Minister of Japan
June 14, 2010
- DSP, JCR Sign Assignment Agreement for Growth Hormone Business
June 14, 2010
- Alfresa Pharma Licenses Tetrabenazine from BLS
June 14, 2010
- 12 APIs NHI-Priced, Including 5 from Takeda
June 14, 2010
- Maruishi, RaQualia Sign Agreement for EP4 Antagonist
June 14, 2010
- AZ Conducts PIII for Arimidex to Obtain Approval for Premenopausal Breast Cancer in Japan
June 14, 2010
- Viviant, E Keppra Recommended for Approval
June 14, 2010
- Sanofi-aventis to Transfer Marketing of Clexane to Kaken
June 14, 2010
- Asahi Kasei Begins PIIa for Pentosan in Osteoarthritis
June 14, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…